What Is Dihexa?
Dihexa, also known by its research designation PNB-0408, is a small peptide compound derived from angiotensin IV — a fragment of the angiotensin cascade best known for its role in blood pressure regulation. However, angiotensin IV's actions in the brain are distinct from its cardiovascular role, and Dihexa was specifically designed to exploit and amplify its central nervous system activity.
Dihexa was developed at Washington State University in the lab of Joseph Harding and Curt Lind, emerging from decades of research into the HGF/c-Met signaling system and its role in synaptic plasticity. The compound's defining claim — that it is approximately seven orders of magnitude more potent than BDNF itself at promoting synaptogenesis in relevant assay systems — comes from peer-reviewed research published in the Journal of Pharmacology and Experimental Therapeutics. This figure requires context: it refers to in vitro potency at specific assay endpoints, not a direct equivalence claim for all BDNF functions in vivo.
What distinguishes Dihexa from virtually every other nootropic compound is its mechanism. Rather than modulating neurotransmitter levels, receptor sensitivities, or neurotrophic factor expression, Dihexa directly engages the biological machinery responsible for the physical formation of new synaptic connections — the structural changes that constitute genuine long-term memory and learning capacity.
Dihexa is classified as an advanced research compound. It is not approved for human use by any regulatory body. Human safety data is extremely limited. This page is presented for educational purposes. Physician oversight is not merely recommended — it is a prerequisite for responsible engagement with this compound.
Mechanism of Action
Dihexa's mechanism is centered on the Hepatocyte Growth Factor (HGF) and its receptor, c-Met — a signaling axis that is critical for long-term potentiation, the cellular basis of learning and memory.
HGF/c-Met Pathway Activation: Dihexa acts as a potent agonist at the HGF receptor (c-Met). HGF is a growth factor with profound effects on neuronal survival, axonal guidance, and — critically — synaptogenesis. Under normal physiological conditions, HGF signaling is tightly regulated and limited in availability. Dihexa effectively supercharges this pathway, producing strong downstream signaling that promotes the physical formation and stabilization of new synaptic connections.
Synaptogenesis: The formation of new synapses — not just the strengthening of existing ones — is Dihexa's most remarkable proposed action. Long-term potentiation (LTP), the mechanism underlying memory formation, typically strengthens existing synaptic connections. True synaptogenesis represents a more fundamental structural remodeling of neural circuits. Animal studies demonstrate that Dihexa-treated animals show measurably increased dendritic spine density in memory-critical regions.
Extraordinary Receptor Affinity: The c-Met binding affinity of Dihexa is exceptional for a small peptide. This high affinity, combined with its ability to cross the blood-brain barrier (which BDNF itself cannot do efficiently), gives it access to brain circuits that neurotrophic factors cannot easily reach through peripheral administration.
Long-Term Potentiation Enhancement: Independent of direct synaptogenesis, Dihexa enhances the magnitude and persistence of LTP in hippocampal circuits — meaning that not only does it support the creation of new synapses, it makes the learning events that occur during its activity window more durable.
Research Benefits
Synaptogenesis
The formation of structurally new synaptic connections — not merely the strengthening of existing ones. Animal studies show measurably increased dendritic spine density following Dihexa treatment.
Long-Term Potentiation
Enhanced magnitude and durability of LTP in hippocampal circuits — the cellular mechanism underlying the conversion of experiences into lasting memories.
Memory Formation & Recall
Animal cognitive testing shows dramatic improvements in spatial memory and learning tasks, with effects persisting well beyond the dosing period — suggesting lasting structural changes.
Alzheimer's Research
Multiple rodent studies in Alzheimer's models demonstrate significant reversal of cognitive deficits, positioning Dihexa as a potential therapeutic lead in neurodegeneration research.
Cognitive Restoration Post-Injury
The synaptogenic mechanism makes Dihexa particularly relevant for cognitive restoration following traumatic brain injury or significant neurological damage where new circuit formation is required.
Dosing & Protocol
| Route | Dose Range | Frequency | Notes |
|---|---|---|---|
| Oral | 10–40 mg | 2–3× per week | Bioavailability variable; consistent timing important |
| SubQ Injection | 1–5 mg | 2–3× per week | Higher bioavailability; use insulin syringe |
Cycle Length: 4–6 weeks is the typical research protocol, followed by an extended break of at least 4–8 weeks. The unusually long off-cycle reflects both the persistent nature of Dihexa's structural effects and the lack of long-term safety data that would justify continuous use.
Starting Protocol: Begin at 10 mg oral (or 1 mg SubQ) twice per week for the first two weeks. Assess cognitive response and any adverse effects before considering dose escalation. Many experienced users report that 20 mg oral twice weekly represents a sufficient dose with a favorable response profile.
Timing: Morning administration is preferred. Dihexa appears to have a long effective window — cognitively demanding activities in the hours following administration may benefit from enhanced LTP during that window.
Risks & Safety
Unknown Long-Term CNS Effects: Promoting synaptogenesis is not inherently dangerous, but the long-term consequences of artificially accelerated synaptic formation in adult humans are not known. Neural circuits are not simply "more connections = better" — the quality, specificity, and pruning of connections matters. The implications of Dihexa's structural CNS changes over years of use are genuinely unknown.
Reported Side Effects: Anecdotal reports from research users include headache, mild irritability, and in some cases vivid dreaming — consistent with the strong neuroplasticity-promoting action. A small number of users report cognitive overstimulation or anxiety at higher doses.
Cancer Biology Caution: HGF/c-Met signaling is implicated in tumor growth and metastasis — c-Met is an oncogene in certain contexts. While the acute research use of Dihexa is unlikely to present meaningful cancer risk in healthy individuals, individuals with a history of c-Met-associated cancers should absolutely not use this compound. This is an area requiring further human safety research.
Physician Oversight: Given the above, physician oversight is not a disclaimer formality — it is a genuine prerequisite for responsible use of this compound. Baseline and follow-up cognitive assessments, bloodwork, and possibly imaging may be warranted in longer protocols.
Stacking Guide
Dihexa's potency means it is typically used as a standalone compound, particularly for first-time users. If stacking is considered, pair with compounds that support the neuroplasticity window it creates rather than adding more stimulatory or synaptogenic load.
Cognitive Load Pairing: Dihexa's synaptogenic action is activity-dependent — the new synaptic connections being formed will be shaped by the cognitive activities you engage in during the dosing period. Users report pairing Dihexa cycles with intensive learning projects, language acquisition, or other demanding cognitive training for best results. This is not merely anecdote — it reflects the neuroscience of activity-dependent plasticity.
What Not to Stack: Avoid combining with other potent HGF/c-Met modulators. Be conservative with other pro-neuroplasticity compounds — the additive effects are not well characterized and the risk of unintended long-term CNS changes increases with stacking complexity.
Access Advanced Protocol Guidance
Join SDBioHack free to access our advanced compound database, physician referral network, and member discussion.
Frequently Asked Questions
This claim originates from the original Washington State University research and refers to Dihexa's potency at inducing synaptogenesis in specific in vitro assay systems — approximately seven orders of magnitude (10 million times) more potent by molar concentration at those endpoints. This is a specific and impressive pharmacological finding, but it requires careful interpretation. It does not mean Dihexa produces 10 million times the neurological effect of BDNF in a living brain. BDNF has dozens of receptor-mediated functions across the entire CNS; Dihexa primarily targets the HGF/c-Met axis. The claim is about receptor binding affinity and one specific downstream effect, not global CNS potency. It is nonetheless remarkable and is the primary reason Dihexa is considered the most potent known synaptogenic compound in research.
This is one of Dihexa's most distinctive and studied characteristics. Animal research demonstrates cognitive improvements that persist for weeks to months after a short dosing period — consistent with the hypothesis that Dihexa's effects are structural (new synapses formed) rather than purely pharmacodynamic (receptor states temporarily altered). Users in the research community report noticing persistent improvements in memory recall and processing speed that extend well beyond the dosing cycle. The structural nature of these changes means that activities learned or memories consolidated during a Dihexa cycle may be more durably encoded. This persistence is also a reason for conservative cycling — the long-term cumulative effects of repeated structural remodeling are not known.
No. Dihexa is explicitly designated as an advanced compound for several reasons: limited human safety data, a potent and structurally impactful mechanism, potential oncological considerations related to c-Met signaling, and the need to recognize and respond appropriately to adverse effects. New researchers should build experience with well-characterized, beginner-appropriate compounds like Semax, Selank, or Noopept — learning how their bodies respond to peptide-based interventions before approaching compounds with Dihexa's profile. Rushing to the most potent available compound is a common mistake with potentially meaningful consequences in this space.
Key References
- McCoy AT, et al. "Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents." Journal of Pharmacology and Experimental Therapeutics, 2013.
- Benoist CC, et al. "Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogues." Journal of Pharmacology and Experimental Therapeutics, 2011.
- Wright JW, et al. "The angiotensin IV/AT4 receptor system regulates the HGF/c-Met signaling pathway." Molecular Neurobiology, 2015.
- Harding JW, et al. "Role of the brain angiotensin system in memory and cognitive function." Neuroscience and Biobehavioral Reviews, 2010.